BioRestorative Therapies Reports Positive Preliminary Phase 2 BRTX-100 Clinical Data
13 nov. 2024 07h00 HE
|
BioRestorative Therapies, Inc
– Blinded preliminary data demonstrate a positive trend and clear signal in Primary and Secondary endpoints – – Patient reported efficacy outcomes show a material decrease in pain and increase in...
BioRestorative Therapies Reports Third Quarter 2024 Financial Results and Provides Business Update
12 nov. 2024 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Nov. 12, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Present New Clinical Data at the ORS PSRS 7th International Spine Research Symposium
06 nov. 2024 07h00 HE
|
BioRestorative Therapies, Inc
– New blinded preliminary safety and efficacy data from the ongoing Phase 2 clinical trial of BRTX-100 to be described in podium presentation on November 13, 2024 – – Data will be on a significantly...
BioRestorative Therapies Receives Expanded Tissue License from New York State Department of Health
05 nov. 2024 07h10 HE
|
BioRestorative Therapies, Inc
– Allows for the processing of allogeneic (non-autologous) donor tissue material, including stem cells, for medical research – MELVILLE, N.Y., Nov. 05, 2024 (GLOBE NEWSWIRE) -- BioRestorative...
BioRestorative Therapies Receives Patent Allowance for ThermoStem® Metabolic Disease Program
31 oct. 2024 07h00 HE
|
BioRestorative Therapies, Inc
– Further expands already formidable intellectual property estate the Company has been building for its novel ThermoStem® technology platform – MELVILLE, N.Y., Oct. 31, 2024 (GLOBE NEWSWIRE) --...
BioRestorative Therapies to Participate in Upcoming UBS and Maxim Group Investor Events
10 oct. 2024 07h00 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 10, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
03 oct. 2024 16h15 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Oct. 03, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies’ IFATS 2024 Presentation to Feature ThermoStem® Platform’s Potential to Deliver a Superior Efficacy and Tolerability Profile Over GLP-1 Drugs
19 sept. 2024 06h55 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Sept. 19, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused...
BioRestorative Therapies Reports Second Quarter 2024 Financial Results and Provides Business Update
13 août 2024 16h05 HE
|
BioRestorative Therapies, Inc
MELVILLE, N.Y., Aug. 13, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem...
BioRestorative Therapies’ Chief Scientist Named New Section Editor of the Prestigious Journal of Translational Medicine
23 juil. 2024 07h10 HE
|
BioRestorative Therapies, Inc
- New journal section will focus on emerging and translation work in the field of regenerative medicine - MELVILLE, N.Y., July 23, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc....